|
|
|
|
|
|
|
Request your FREE Special Report today and you'll |
Biopharmaceutical company Repligen Corp. (Nasdaq:RGEN) said this morning that it will repurchase of up to 1.25 million shares of its common stock, stating that the program “reflects the confidence it has in its business.”
Shares were halted in pre-market trading. For detailed price information and recent news stories about Repligen, click RGEN.
Join Daily Profit today and get our unique perspective and investment ideas in your inbox every day.
Please tell us where we can send your free subscription. Plus, as a free gift, I'll rush you a copy of my Top 10 Forever Stocks - a special bonus report.
Wyatt Investment Research
c/o Business Financial Publishing
65 Railroad Street
PO Box 790
Richmond, VT 05477
